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Recent genetic association studies have made progress in uncovering components of the genetic architec-
ture of the body mass index (BMI). We used the ITMAT-Broad-Candidate Gene Association Resource (CARe)
(IBC) array comprising up to 49 320 single nucleotide polymorphisms (SNPs) across ∼2100 metabolic and
cardiovascular-related loci to genotype up to 108 912 individuals of European ancestry (EA), African-
Americans, Hispanics and East Asians, from 46 studies, to provide additional insight into SNPs underpinning
BMI. We used a five-phase study design: Phase I focused on meta-analysis of EA studies providing individual
level genotype data; Phase II performed a replication of cohorts providing summary level EA data; Phase III
meta-analyzed results from the first two phases; associated SNPs from Phase III were used for replication in
Phase IV; finally in Phase V, a multi-ethnic meta-analysis of all samples from four ethnicities was performed.
At an array-wide significance (P < 2.40E-06), we identify novel BMI associations in loci translocase of outer
mitochondrial membrane 40 homolog (yeast) - apolipoprotein E - apolipoprotein C-I (TOMM40-APOE-
APOC1) (rs2075650, P 5 2.95E-10), sterol regulatory element binding transcription factor 2 (SREBF2,
rs5996074, P 5 9.43E-07) and neurotrophic tyrosine kinase, receptor, type 2 [NTRK2, a brain-derived neuro-
trophic factor (BDNF) receptor gene, rs1211166, P 5 1.04E-06] in the Phase IV meta-analysis. Of 10 loci
with previous evidence for BMI association represented on the IBC array, eight were replicated, with the
remaining two showing nominal significance. Conditional analyses revealed two independent BMI-asso-
ciated signals in BDNF and melanocortin 4 receptor (MC4R) regions. Of the 11 array-wide significant
SNPs, three are associated with gene expression levels in both primary B-cells and monocytes; with
rs4788099 in SH2B adaptor protein 1 (SH2B1) notably being associated with the expression of multiple
genes in cis. These multi-ethnic meta-analyses expand our knowledge of BMI genetics.
INTRODUCTION
Obesity is a complex disorder affecting more than one-third of
the US adult population (1,2) and approximately half a billion
people worldwide (3). Obesity increases the risk of metabolic
conditions such as cardiovascular diseases (CVDs) (4,5), type 2
diabetes (T2D) (6), hyperlipidemia (7) as well as certain
cancers (8). Although sedentary behaviors and poor nutrition
certainly contribute to the pathogenesis of obesity, genetic
variation also plays a role, with estimated heritability
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ranging from 40% to as high as 90% (9–11). As of March
2012, common genetic variants in 32 human loci from
genome-wide association studies (GWAS) have been reported
to be associated with the body mass index (BMI) in indivi-
duals of European ancestry (EA) (12–16). These studies
have specifically searched for and identified common genetic
variants that associate with BMI in individuals of EA and
follow an additive genetic model. Variants that are rare in
individuals of EA but may be more common in other ances-
tries, or those loci that require environmental exposures that
differ by the population subgroup, exist and require
approaches beyond standard GWAS in only European-based
samples to be identified (17,18).
In this study we aimed to identify BMI-associated variants that
may have been missed by previous studies and sought to confirm
previously reported associations. We used the ITMAT-Broad-
CARe (IBC) array (19), also referred to as the CardioChip or
the human CVD BeadChip (Illumina, San Diego, CA, USA),
which comprises up to 49 320 single nucleotide polymorphisms
(SNPs) selected across 2100 metabolic and cardiovascular-
related loci with variation in most targeted genes captured at a
density greater or equal to the standard genome-wide genotyping
arrays. Content was selected for the IBC array using data from
first waves of CVD-related GWAS results, additional high-
priority candidate genes of interest and analysis of cardiovascu-
lar, inflammatory and metabolic pathways. Robust associations
have been shown on the IBC array for a range of phenotypes in-
cluding coronary artery disease (20,21), heart failure (22,23),
lipids (24), height (25) and T2D (26).
Ten of the 32 GWAS-identified BMI loci reported to date
are included on the IBC array; however, many genes with
plausible roles in metabolism and in the etiology of obesity,
but which have not previously been implicated, are specifical-
ly tagged on the array. SNP selection included the use of rese-
quencing data from the SeattleSNPs and National Institute of
Environmental Health Sciences (NIEHS) SNP consortia, as
well as the International HapMap Consortium, to ensure
deeper capture of variation within genes of interest. The IBC
array was enriched for uncommon SNPs, as .17 000 included
SNPs have minor allele frequency (MAF) ,0.05 in test popu-
lations of EA, with the inclusion of putative functional SNPs
from the literature and non-synonymous SNPs (7.7% of the
total number of IBC array SNPs) (19).
Conditional analysis in additional complex phenotypes,
such as height (25) and plasma lipids (27), has revealed loci
containing multiple independent signals which are strong
plausible sources to explain portions of the ‘missing’ genetic
variance. Suitable sample sizes and dense loci coverage are
required to perform conditional analysis. Furthermore the con-
sistency of an association signal observed across multiple eth-
nicities increases confidence in the validity of the signals (28).
Finally, variability in signal strength between populations, e.g.
due to different allele frequencies or patterns of linkage dis-
equilibrium (LD), may allow for novel signals to be identified
in different ethnic groups.
In the current study, we perform large-scale BMI meta-
analysis on 92 903 individuals of EA, 12 297 African-
Americans, 2625 Hispanics and 1087 East Asians across 46
separate studies. We directly queried common and uncommon
genetic variants within this targeted array with the aim of
validating known BMI loci in these different ethnicities as
well as discovering novel BMI-associated loci. We performed
primary analyses (Fig. 1; left shaded panel) of discovery and
replication for BMI-associated signals by using population-
specific and multi-ethnic approaches, and we also conducted
secondary calculations (Fig. 1; right shaded panel) including
conditional analysis to search for multiple independent
signals within associated loci, sex-specific associations
testing for sex-related differences in BMI association and
two other additional meta-analyses in an attempt to further
validate our findings.
RESULTS
Meta-analysis of individuals of European ancestry
replicates known BMI signals and reveals novel BMI
associations in the TOMM40-APOE-APOC1, SREBF2
and NTRK2 loci
BMI meta-analysis using the IBC array was initially per-
formed in cohorts of EA which provided individual-level
data (Phase I in Fig. 1; n ¼ 50 933). We observed six array-
wide significant lead signals (Table 1): rs1421085 in the fat
mass and obesity associated (FTO) locus, rs2272903 in tran-
scription factor activating enhancer binding protein 2 beta
(TFAP2B), rs10767664 in brain-derived neurotrophic factor
(BDNF), rs12617233 in Fanconi anemia, complementation
group L (FANCL)-FLJ30838, rs2075650 in translocase of
outer mitochondrial membrane 40 homolog (yeast)-apolipo-
protein E-apolipoprotein C-I (TOMM40-APOE-APOC1) and
rs2229616 (also known as V103I) in melanocortin 4 recep-
tor(MC4R). One of the findings, the TOMM40-APOE-APOC1
locus is previously unreported. The uncommon SNP
rs2229616 (MAF ¼ 0.02) in MC4R was reported to be asso-
ciated with obesity in two independent studies (29,30), but
never reached genome-wide significance (P , 5.00E-08).
Cohorts providing unpublished summary-level association
results (Phase II in Fig. 1; n ¼ 27 503) provided nominal evi-
dence for replication (P ≤ 2.45E-03) in four of the six array-
wide significant associated SNPs from the individual-level
data: the FTO, BDNF, MC4R and TOMM40-APOE-APOC1
SNPs (Table 1).
Meta-analysis was then performed including both
individual- and summary-level cohorts of EA (Phase III in
Fig. 1; n ¼ 78 436). All signals of association identified in
individual-level cohorts remained in this phase, with
three additional signals revealed: rs997295 in mitogen-acti-
vated protein kinase kinase 5 (MAP2K5), rs4704220 in colla-
gen, type IV, alpha 3 (Goodpasture antigen) binding protein
(COL4A3BP) - 3-hydroxy-3-methylglutaryl-CoA reductase
(HMGCR) and rs4788099 in SH2B adaptor protein 1
(SH2B1). In total, nine loci were associated with BMI at array-
wide significance (P , 2.40E-06, shown in bold in Table 1)
with five loci surpassing the traditional genome-wide signifi-
cance threshold (P , 5.00E-08, shown in bold italic in
Table 1). These results provide replication of the well-
established BMI association signals in FTO (12–16) and
BDNF (14,16), which serves as robust positive controls of
our study design. Further examination of the novel SNP in
TOMM40-APOE-APOC1 is shown for each cohort using a
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forest plot in Figure 2. Forest plots for all the other eight top
signals in Phase III can be found in Supplementary Material,
Figures S1–S8.
In Phase IV we selected a list of 29 look-up SNPs including
positive controls, borderline signals and those in LD with
SNPs in previously reported BMI loci (see Methods
Section), and interrogated them in six additional look-up
studies serving as another replication data set. After perform-
ing meta-analysis incorporating the new data, two novel
signals, rs5996074 in sterol regulatory element binding tran-
scription factor 2 (SREBF2; P ¼ 9.43E-07) and rs1211166 in
neurotrophic tyrosine kinase, receptor, type 2 [NTRK2, a
brain-derived neurotrophic factor (BDNF) receptor gene;
P ¼ 1.04E-06], became associated with BMI at array-wide
significance (Table 1; for forest plots, see Supplementary
Material, Figs S9 and S10). All the other Phase III top
SNPs showed stronger evidence of association, except
SNPs rs997295 in MAP2K5 and rs4704220 in the
COL4A3BP-HMGCR locus, for which P-values weakened
slightly (Table 1). Moreover, all heterogeneity measures (I2
values) are less for the Phase IV meta-analysis than for
those in Phase III (Table 1), except for the case of FTO.
As all cohort-specific analysis was conducted in a sex-
stratified manner, meta-analysis of each sex was performed
and the results were compared for concordance between
males and females. All signals identified had concordant direc-
tion of effect in males and females. Marginal heterogeneity
was observed at rs997295 (MAP2K5), where the genetic
signal was stronger in males (males P ¼ 5.50E-06; females
P ¼ 8.03E-02; heterogeneity P ¼ 0.04; Supplementary Mater-
ial, Table S1).
The Phase IV meta-analysis results provide replication and
validate five loci SH2B1, MAP2K5, TFAP2B, FANCL-
FLJ30838 and COL4A3BP-HMGCR, which were recently
identified by Speliotes et al. (16) in the Genetic Investigation
of Anthropometric Traits (GIANT) consortium (Table 1), in
addition to the three previously reported BMI loci: FTO,
MC4R and BDNF. Further examination provided replication
in 8 of the 10 GIANT loci that are represented on the IBC
array with adequate coverage. Two loci, TNNI3 interacting
kinase (TNNI3K) and gastric inhibitory polypeptide receptor
(GIPR) (with previously reported lead SNPs rs1514175 and
rs2287019, respectively) did not reach array-wide significance
in the Phase III meta-analysis, but marginal significance was
observed with consistent direction of effect (Table 2 and Sup-
plementary Material, Table S2). To calculate the extent of
variation explained by the associated and validated SNPs
from Phase IV, we returned to Phase I cohorts with individual-
level phenotype and genotype data available. The variation
explained by each SNP individually was limited ranging
from 0.01 to 0.37% per SNP (Table 1).
Conditional analysis reveals two independent BMI
signals in MC4R and BDNF
We performed conditional analysis to identify loci containing
multiple variants independently influencing BMI. In cohorts
where individual-level data were available, regression analysis
was repeated including an additional term to adjust for the
effect of the lead SNP identified in the overall EA
meta-analysis. Two loci, BDNF and MC4R, were shown to
contain an additional independent signal (Table 3; Fig. 3).
Figure 1. Schematic design of study for genetic association between BMI and genetic markers in the ITMAT-Broad-CARe (IBC) array. The work flow includes
three parts, which are within study procedures, primary analyses and secondary analyses. Details can be found in the text.
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Table 1. Primary results for BMI association analysis using the ITMAT-Broad-CARe (IBC) array
Locus
rank



















Effect P-value Effect P-value I2 Effect P-value I2
1 FTO 16q12.2 rs1421085 52 358 455 C 0.42 0.086 7.75E-40 0.37 0.097 1.38E-27 0.090 1.57E-65 16 0.089 1.26E-73 18 1.35E-69 17434869; 2007
2 BDNF 11p13 rs10767664 27 682 562 A 0.79 0.041 3.48E-07 0.03 0.044 2.85E-05 0.042 4.57E-11 0 0.043 3.40E-13 0 7.87E-14 19079260; 2008
3 MC4R 18q22 rs2229616 56 190 256 C 0.98 0.111 1.96E-06 0.04 0.130 6.11E-05 0.118 5.28E-10 10 0.112 2.82E-10 0 6.39E-12 18454148; 2008g
4 TOMM40-APOE-APOC1 19q13 rs2075650 50 087 459 A 0.86 0.045 6.70E-07 0.09 0.037 2.47E-03 0.042 6.87E-09 11 0.042 2.95E-10 1 5.99E-11 —
5 SH2B1 16p11.2 rs4788099 28 763 228 G 0.39 0.031 2.20E-05 0.06 0.022 2.39E-02 0.028 1.92E-06 13 0.031 7.30E-09 12 1.87E-07 20935630; 2010
6 FANCL-FLJ30838 2p16.1 rs12617233 58 893 502 C 0.60 0.035 1.23E-07 0.06 0.015 8.67E-02 0.028 1.41E-07 9 0.028 8.25E-09 3 5.54E-09 20935630; 2010
7 TFAP2B 6p12 rs2272903 50 894 530 G 0.90 0.056 1.07E-07 0.09 0.023 1.43E-01 0.045 2.84E-07 30 0.043 7.61E-08 23 4.53E-09 20935630; 2010
8 MAP2K5 15q23 rs997295 65 803 397 T 0.59 0.024 3.08E-04 0.04 0.039 1.44E-05 0.029 4.09E-08 10 0.026 2.48E-07 10 1.43E-08 20935630; 2010
9 COL4A3BP-HMGCR 5q13.3 rs4704220 74 793 312 G 0.61 0.029 9.99E-06 0.04 0.023 9.80E-03 0.027 3.68E-07 1 0.025 4.19E-07 0 1.04E-07 20935630; 2010
10 SREBF2 22q13 rs5996074 40 566 283 A 0.70 0.022 1.68E-03 0.05 0.027 5.03E-03 0.024 2.72E-05 15 0.026 9.43E-07 8 1.93E-07 —
11 NTRK2 9q22.1 rs1211166 86 475 812 A 0.80 0.029 3.75E-04 0.01 0.025 2.66E-02 0.027 2.97E-05 0 0.029 1.04E-06 0 2.87E-08 —
Chr., chromosome; % var, average variance explained (adjusted R2) in Phase I cohorts weighted by cohort sample size; I2, heterogeneity measurement.
Eleven signals reached the array-wide significance level after Phase IV meta-analysis of European ancestry samples from individual-level, summary-level and look-up studies.
The table is sorted by P-values in Phase IV meta-analysis. All SNPs mapped back to NCBI build 36 (UCSC hg18) human reference genome. P-values passing the array-wide significance cut-off of 2.40E-06 are highlighted in
bold, and P-values less than the conventional genome-wide significance of 5.00E-08 are further annotated in Italics.
aEff. All. Freq., effect allele frequency estimated from Phase IV meta-analysis.
bSample size up to 50 933.
cSample size up to 27 503.
dSample size up to 78 436.
eSample size up to 92 903.
fSample size up to 108 912.
































Figure 2. Forest plots for the novel finding rs2075650 at the translocase of outer mitochondrial membrane 40 homolog (yeast)-apolipoprotein E-apolipoprotein
C-I (TOMM40-APOE-APOC1) locus of genetic association between BMI and ITMAT-Broad-CARe (IBC) SNPs. Name of participating study, number of
samples entering the meta-analysis, minor allele frequency (MAF) and effect size together with 95% confidence interval (CI) are shown as indicated by the
header line of each plot. Effect sizes of meta-analysis results are shown at the bottom of each plot. Studies are sorted by sample size and are grouped according
to ethnicities and data-contributing type (individual level or summary level). Sub-meta-analysis results are also shown where applicable.
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In BDNF, after conditioning on SNP rs10767664 a second
SNP rs1401635 showed locus-wide significance (P ¼ 1.00E-04;
between-SNP LD measures: r2 ¼ 0.115,D′ ¼ 0.995). Similarly
in MC4R, after conditioning on rs2229616, an additional SNP,
rs17066846, showed locus-wide significance (P ¼ 1.05E-04;
between-SNP LD measures: r2 ¼ 0.005, D′ ¼ 1.000). For
each locus, when both independent signals were incorpo-
rated in the regression model, no further signals became
stronger than the locus-wide significance threshold. Interest-
ingly, in both loci the lower MAF SNP was the lead
SNP and the minor allele in the lead SNP was never
observed on the same haplotype as the minor allele at the
secondary SNP signal (resulting in a high level of D′).
However, in both cases the genotype at one SNP was not
a good predictor of the genotype at the other SNP (resulting
in the low r2).
Meta-analysis of additional ethnicities reveals the
consistency and strengthened the significance of
BMI-associated variants identified in European ancestry
BMI meta-analysis limited to the cohorts containing
African-Americans, Hispanics and East Asian individuals
did not reveal any array-significant association, the likely
result of lower power afforded by the smaller sample sizes.
Comparison of meta-analysis results in those populations for
variants associated with BMI in EA samples are shown in Sup-
plementary Material, Table S3. Regional plots representing
genomic context around loci with top BMI-association SNPs
were generated using LocusZoom (31) for TOMM40-
APOE-APOC1 (Fig. 4) as well as FTO, BDNF, MC4R,
COL4A3BP2HMGCR and SH2B1 loci (Supplementary
Material, Figs S11–S15). Histograms of the distribution of
observed effects are outlined in Supplementary Material,
Figure S16. The width of the distribution of observed effects
was larger in the non-European ethnicities due to fewer
cohorts and the smaller sample sizes. Of 11 SNPs identified
in EA cohorts in Phase IV, 6 (FTO, BDNF, MC4R,
FANCL-FLJ30838, TFAP2B and NTRK2) were observed to
be nominally associated, with the same direction of effect,
in the African-American cohorts (P, 0.05; Supplementary
Material, Table S3). Only one of the signals (rs4788099 in
SH2B1) is of opposite effect direction in samples of
African ancestry, but the effect is very close to zero. No var-
iants were associated in Hispanics or East Asians, which is
again likely due to their limited power due to small
sample sizes. The estimated direction of effect was concord-
ant for 7 of 11, and 6 of 11, lead SNPs in Hispanics
and East Asians, respectively (Supplementary Material,
Table S3).
In the global multi-ethnic meta-analysis, we interrogated all
92 903 individuals of EA, 12 297 African-Americans, 2625
Hispanics and 1087 East Asians (total n ¼ 108 912). Of the
11 SNPs found in the Phase IV meta-analysis including
every cohort of EA, nine achieved greater evidence for associ-
ation in the global multi-ethnic meta-analysis. As for the
remaining two signals, the top BMI-associated SNP
rs1421085 (in the FTO gene) showed weaker evidence for as-
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the SH2B1 locus) became weaker but still met array-wide sig-
nificance (Table 1; Fig. 1). We observed one additional variant
surpassing the array-wide significance, rs11672660 in GIPR
(effect allele C, effect ¼ 0.027 and P-value ¼ 1.58E-06)
which is the same index SNP of borderline significance in
the Phase IV meta-analysis (Table 2). This result also
ensured validation of the previously reported BMI association
of GIPR.
Exclusion of CVD enriched sample confirms the robust
nature of the observed BMI associations identified from
our cohorts of European ancestry
As some participating studies in this meta-analyses recruited
individuals using case–control or clinical trial ascertainment
criteria, we sought to reduce the potential bias effects of en-
richment for CVD status. We repeated the BMI meta-analysis
Table 3. Conditional analysis showing two loci harbor independent signals in BMI association with ITMAT-Broad-CARe (IBC) SNPs after conditioning on the
lead SNP















Effect P-value Effect P-value
MC4R 16 rs2229616 56190256 C 0.98 0.111 1.71E-06 — — — —
rs17066846 56195798 G 0.19 0.040 3.29E-05 0.038 1.05E-04 0.005 1
BDNF 13 rs10767664 27682562 A 0.21 0.041 2.41E-07 — — — —
rs1401635 27650567 C 0.30 0.037 1.46E-07 0.029 1.00E-04 0.115 0.995
Eff. All. Freq., effect allele frequency.
Data based on all Phase I European ancestry samples (n ¼ 50 933). All SNPs mapped back to NCBI.
Figure 3. Regional plots for the melanocortin 4 receptor (MC4R) and brain-derived neurotrophic factor (BDNF) region before and after doing conditional ana-
lysis. Two MC4R sub-figures are to the left panel and two BDNF sub-figures are to the right. For each locus, the top part shows unconditional meta-analysis
results for individual-level samples of European ancestry (EA) and the bottom part shows meta-analysis results conditioning on lead SNP, rs2229616 in
MC4R and rs10767664 in BDNF, respectively. Figures were generated using LocusZoom (31).
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but included only samples from the population- or community-
based and control-only cohorts using individuals of EA (n ¼
48 241). Compared with Phase III results, five of the nine
signals remain at array-wide significance, whereas four
others were only marginally associated with BMI (P ≤
1.18E-04; Supplementary Material, Table S4). The relative
effect size and effect direction remained concordant in all
nine SNPs, suggesting the reduction in statistical evidence is
most likely a result of the reduction in sample size.
As some cohorts in this study also participated in the recent
GIANT BMI GWAS meta-analysis (16), we performed an
additional analysis to assess BMI associations within cohorts
not represented in the GIANT meta-analysis. Five of the
nine loci were significant at the array-wide threshold in the
IBC ‘non-GIANT’ meta-analysis while the remaining four
SNPs showed marginal evidence for association (P ≤
1.51E-04; Supplementary Material, Table S2). Interestingly a
previously undescribed signal in CADM1 (rs3802858) was
still near the array-wide significance threshold, with P ¼
9.26E-06 (versus 4.45E-06 when we include IBC data from
GIANT cohorts; see look-up SNP list in Supplementary
Material, Table S5) and intriguingly a gene in the same func-
tional group, CADM2, was documented to be associated with
BMI in the GIANT study (Supplementary Material, Table S2).
However after performing association meta-analysis including
the look-up studies, this particular SNP did not replicate.
eQTL analyses of the eleven BMI-associated loci reveals
multi-loci cis-acting eQTLs for the associated SH2B1 SNP
in both purified primary B-cells and monocytes
We attempted to assess functionality of the 11 BMI SNPs
found to be associated at array-wide significance using expres-
sion QTL (eQTL) analysis in two distinct primary cell types:
B-cells and monocytes. The cis eQTL findings for the array-
wide significant SNPs with the Spearman test P ≤ 7.00E-05
are shown in Supplementary Material, Table S6. We observed
that three of the BMI-associated SNPs either form, or are in
LD to SNPs that are eQTL. Most notable of these eQTL
include the rs4788099 variant in SH2B1 which forms multi-
loci cis eQTLs in both primary B-cells and primary mono-
cytes. Supplementary Material, Figure S17 illustrates that
Figure 4. Regional plots of the TOMM40-APOE-APOC1 region for multi-ethnic association between BMI and ITMAT-Broad-CARe (IBC) array SNPs.
Meta-analysis regional results of overall European ancestry individuals (top left), African-American (bottom left), East Asians (top right) and Hispanics
(bottom right) are shown using LocusZoom (31). In each sub-figure, each spot represents one IBC SNP and its y-axis coordinate indicates significance level
in association. For each SNP, linkage disequilibrium (LD) measure r2 with the lead SNP can be determined from the inset color scheme. Genome recombination
rates (in cM/Mb) are shown by blue lines and gene annotation information can be found at the bottom.
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rs4788099 forms a multi-loci cis eQTL to probes in spinster
homolog 1 (Drosophila) (SPNS1) with PB-Cell ¼ 4.25E-10
and also to probes in Tu translation elongation factor, mito-
chondrial (TUFM) with PB-Cell ¼ 4.69E-37. A multi-loci cis
eQTL is also evident for rs4788099 in primary monocytes to
probes in five loci (Supplementary Material, Fig. S17):
coiled-coil domain containing 101 (CCDC101; Pmonocyte ¼
1.14E-06 and 4.90E-06); SPNS1 (Pmonocyte ¼ 3.46E-10); sul-
fotransferase family, cytosolic, 1A, phenol-preferring, member
1 (SULT1A1; Pmonocyte ¼ 5.34E-06); sul-fotransferase family,
cytosolic, 1A, phenol-preferring, member 4 (SULT1A4;
Pmonocyte ¼ 1.43E-10) and TUFM (Pmonocyte ¼ 1.83E-29).
DISCUSSION
In a meta-analysis of gene-centric association studies of BMI
encompassing 92 903 individuals of EA (Phase IV as illu-
strated in Fig. 1), we identified three novel BMI associations:
the TOMM40-APOE-APOC1 locus at genome-wide signifi-
cance (P ≤ 1.49E-08), and SREBF2 and NTRK2 genes at
array-wide significance (P ≤ 1.04E-06). We also observed as-
sociation in three previously established BMI genes (FTO,
BDNF and MC4R) and replicated five loci (FANCL-
FLJ30838, SH2B1, TFAP2B, MAP2K5 and COL4A3BP-
HMGCR) first identified in the recent GIANT BMI analysis
(16). Two additional loci described in GIANT and captured
on the array showed nominal evidence for association with
BMI (TNNI3K, GIPR). Conditional analysis identified two
loci each containing two independent signals within BDNF
and MC4R. Utilizing SNP data in up to 108 912 individuals
and considering ancestry as a covariate, we also conducted a
multi-ethnic meta-analysis (Phase V in Fig. 1), with the
result showing stronger signals for all but two top findings
in the Phase IV result.
Among the novel findings in the current investigation, the
lead BMI SNP (rs2075650) lies within an intron of
TOMM40. The LD structure spanning the TOMM40-APOE-
APOC1 locus precludes more discrete localization of the
causal signal(s) with the available data. The G allele of
rs2075650, associated with lower BMI in the current report,
has been reported to be associated with elevated Alzheimer’s
disease risk (32) increased total cholesterol concentrations
(33) and longevity (34,35). In data from the 1000 Genomes
Project, no LD is observed between rs2075650 and either of
the APOE isoform-determining SNPs in Europeans. Associa-
tions between the functional APOE 12/13/14 isoforms and cir-
culating lipid concentrations have been known for over 25
years (36). Subsequently, association between the APOE iso-
forms and elevated risk for CVD and Alzheimer’s disease
was identified. The three isoforms are captured by SNPs
rs7412 and rs429358, but unfortunately the SNPs either
failed quality control metrics in this study (and generally do
not perform well in microarray-based genotyping due to
nearby nucleotide sequences, and as such are often not
included genome-wide data sets) or was not included in the
SNP panel used to perform meta-analysis and were thus not
directly available in the current investigation. No BMI associ-
ation was observed for a SNP in LD with the APOE isoform-
determining SNPs. It remains unclear at this point if APOE or
one of the other gene products in the locus is responsible for
the observed effects.
While the TOMM40-APOE-APOC1 locus has not been pre-
viously associated with BMI, the forest plot (Fig. 2) of
rs2075650 shows the association is strongly consistent
across the cohorts investigated, including across ethnicities,
increasing our confidence in the authenticity of the associ-
ation. Inadequate coverage of the area in previous BMI asso-
ciation studies is not likely responsible, as rs2075650 is
included in the main Illumina genome-wide genotyping pro-
ducts and the International HapMap Project, and a P-value
of 0.0237 with effective sample size of 111 450 was observed
in GIANT consortium data (16) (obtained via online
GIANT consortium data files at http://www.broadinstitute.org/
collaboration/giant/index.php/GIANT_consortium_data_files;
date last accessed September 2012). Heterogeneity of the
signal in different populations is a possible reason for no pre-
vious report, but the wide range of study types included in this
meta-analysis argues against this. Analysis by Speliotes et al.
(16) indicates that over 250 common variant loci are predicted
to contribute to the distribution of BMI across the population.
Even with extremely large sample sizes the power to identify
variants with small effects is not complete (37). Thus, random
chance may be the most likely explanation why association
between BMI and the TOMM40-APOE-APOC1 locus has
not been previously discovered.
The rs5996074 intronic variant lies within the ubiquitously
expressed SREBF2 gene . The protein product, SREBF2, has
many known roles for modulating transcription of genes
involved in fatty acid and cholesterol metabolism including
3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase and
ATP-binding cassette transporter A1(ABCA1). As well, the
locus contains the microRNA-33a/b, further controlling lipid
metabolism (38). However, no genetic variant within
SREBF2 has previously been associated with either plasma
lipid concentrations or BMI in high-throughput analyses.
The rs1211166 intronic variant lies in NTRK2, which is a re-
ceptor of BDNF. Like BDNF, NTRK2 has been implicated in
the regulation of mammalian eating behavior and energy
balance (39). Mouse models with an Ntrk2 mutation resulting
in only 25% of typical expression levels have been shown to
develop obesity (40). BDNF and NTRK2 have several add-
itional roles in processes such as learning, sensation,
memory and locomotor behavior (41). Furthermore, Yeo
et al. (42) have described a de novo loss-of-function mutation
in NTRK2 associated with severe early-onset obesity, hyper-
phagia, developmental delay and other defects in higher
neurological functions in a child patient.
Rare mutations within the MC4R were first identified to be
segregating in families with extreme obesity in a monogenic
fashion. Subsequently, many functional mutations have been
identified in children selected for sequencing due to extreme
obesity, accounting for up to 6% of childhood obesity cases
(43). Common SNPs have been repeatedly reported to be asso-
ciated with multiple measures of obesity with small effect
throughout the population (15). Interestingly, the SNP
showing the strongest MC4R association in the current study
was the functional (44) and uncommon rs2229616, with an
MAF of 2% in individuals of EA. The observed effect size
of rs2229616 is modest in size (b ¼ 20.12 per minor allele
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T), but was the largest effect of all associated variants in the
current study. The allele frequency and effect was similar
across the other three examined ethnicities. SNP rs2229616
represents an uncommon polymorphism with modest effect
that could only be successfully replicated at the genome-wide
significance level through the large sample sizes and dense
genotyping provided by the study design of the current inves-
tigation.
Conventional GWAS studies have lacked direct coverage or
effective imputation of many low frequency variants. Imput-
ation is often performed to increase the number of queried
SNPs in GWAS efforts by using phased haplotype data from
panels of densely genotyped individuals, such as those pro-
vided by the HapMap and 1000 Genomes Project (45).
Because the IBC array contains many SNPs with MAFs
,5% and a large number of individuals have been genotyped
on the array, it provides a unique opportunity and sufficient
power to directly test for the association of lower frequency
variants with relatively small effect sizes. In the current
meta-analysis, one low frequency variant in MC4R with
MAF 0.02 was shown to be associated with BMI.
The results of large-scale genetic association meta-analyses
are important for identifying robust and valid associations that
shed new light onto important genes and biological pathways,
and that the results can be combined to have a larger effect on
predicted heritability. The results of large-scale genetic associ-
ation meta-analyses are important for identifying robust
and valid associations that shed new light onto important
genes and biological pathways, and that the results can be com-
bined to have a larger effect on predicted heritability. It is a stat-
istical inevitability that if extremely large sample sizes are
required to confidently identify and confirm a signal, the
effect of the identified signals need be either small, relatively
heterogeneous in effect or that are from variants with lower
minor allele frequency. It is clear that a wide spectrum of
variant types and frequencies, and interactions between them
and the environment, as well as the possibility of new discover-
ies, will be required to fully explain the heritability of BMI.
Genes identified from monogenic disorders influencing
height and lipid levels have been subsequently shown to
contain common SNPs associated with the respective pheno-
types across its distribution in the population. As the power
of genetic association studies improves with increasing
sample size, more examples of this pattern have become ap-
parent. Common variants that are not identified within genes
associated with monogenic disorders and genes with
common variants that do not appear to be mutated in mono-
genic forms of the disease, may provide additional clues to
the role of the particular gene in the etiology of the disease.
Of 21 genes mutated in monogenic forms of obesity (46), 16
were adequately represented on the IBC array (Supplementary
Material, Table S7), but only MC4R and BDNF were found to
be associated with BMI, providing insight into the role of
common and uncommon variants in the genetic architecture
of obesity. Why there appears to be fewer obesity-associated
common SNPs in ‘monogenic obesity’ genes, when compared
with other traits, is yet to be understood. Several current initia-
tives will further assess whether obese individuals have an
over-representation of disruptive rare variants in genes with
common obesity-associated SNPs.
Association testing conditioned on the genotype of the iden-
tified lead SNPs revealed two loci, MC4R and BDNF, that
each appear to harbor at least two independent signals of asso-
ciation. The observed independently associated SNPs are
physically close to the lead SNPs (5 and 32 kb, respectively),
and no recombination hotspot lies between them. In both loci,
the two SNPs represent mutations on an ancestral haplotype
that have become more common in the population, thus the
rare alleles at the two SNPs are never observed on the same
haplotype yielding D′ ¼ 1. As the common genotype at
either SNP gives little information regarding the genotype at
the other SNP, the r2 remains low (with r2 of 0.005 and
0.115, respectively). Association of two independent, though
different, SNPs with BMI has been previously reported
within MC4R (16). With .30 functional mutations reported
in MC4R (47), allelic heterogeneity at the locus is well estab-
lished. Similarly, independent BMI-associated SNPs have also
been reported within BDNF (14); thus the current study repli-
cated findings of allelic heterogeneity in the genetic architec-
ture of BMI.
Using eQTL analyses in two distinct primary cell-types with
divergent functions, B-cells and monocytes, we found strong
multi-loci cis eQTLs for the rs4788099 variant in SH2B1
with both SULT1A1 and TUFM. Interestingly Gutierrez-
Aguilar et al. (48) recently demonstrated that in high-fat diet
versus chow-fed rats SH2B1 is down-regulated in the hypo-
thalamus and that the mRNA levels of SULT1A1 were down-
regulated in the adipose tissue of rats fed on high-fat diet,
whereas TUFM was up-regulated. Furthermore, SULT1A1
and TUFM were shown to be up-regulated in the livers of
high-fat diet rats versus chow-fed rats.
In conclusion, in the current study of 108 912 individuals
from 46 cohorts including four ethnicities, we identify three
novel BMI signals in TOMM40-APOE-APOC1, NTRK2 and
SREBF2, and confirmed genetic associations in an additional
eight loci recently reported by the GIANT consortium. Two
independent signals of association were identified in both
MC4R and BDNF. Although individual examinations of the
additional ethnic groups were not powered to adequately rep-
licate specific findings from European cohorts, combined ana-
lyses did increase the strength of associations.
MATERIALS AND METHODS
Study design
Figure 1 illustrates the overall study design. Five primary ana-
lyses were undergone, including discovery (Phase I) and rep-
lication (Phase II, III and IV) of BMI-associated signals in
European descendants, and meta-analysis including additional
ethnicities (Phase V). Quality control of phenotype (BMI),
genotype (SNPs) and covariates (age, ethnicity, disease
status etc.) was performed in each cohort independently, re-
gardless of whether providing individual-level data (Phase
1), cohort association results (Phase II) or lookup SNP
results (Phase IV). Four secondary analyses were performed
including conditional association, sex-specific tests, analyses
limited to healthy controls and meta-analysis of cohorts not
present in the recent GIANT BMI GWAS (16).
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Participating studies
In total, 24 studies contributed individual-level genotype, BMI
and covariate data (self-reported ethnicity, sex, age at meas-
urement, study site information) for a total of 64 440 partici-
pants (Phase I, Supplementary Material, Table S8). Sixteen
studies contributed summary-level association results from a
standardized analysis guideline, representing an additional
27 868 subjects (Phase II, Supplementary Material,
Table S9). Finally six studies of 16 604 samples served as a
further layer of replication (Phase IV, Supplementary Mater-
ial, Table S10), where top association SNPs from Phase III
meta-analysis were interrogated as look-ups, creating an
overall total sample size of 108 912. Participating data sets
included population-based cohorts, collections of cases and
controls for a variety of metabolic and cardiovascular pheno-
types, and individuals collected for clinical trials (Supplemen-
tary Material, Tables S8–10). All participating studies
obtained informed consent for DNA analysis and received ap-
proval from local institutional review boards. Detailed
summary statistics for participants’ BMI and age for each
study is shown in Supplementary Material, Tables S11–13.
Genotyping and quality control
Genotyping was performed using the gene-centric IBC array,
whose design and use has been described in detail elsewhere
(19). Up to 49 320 SNPs were clustered into genotype calls
using the BeadStudio software (Illumina) and subjected to
quality control filters at the sample and SNP level, separately
within each cohort. Samples were excluded where individual
call rates were ,90% and where sex mismatches between
the genetic data and reported value were observed. SNPs
were removed for call rates of ,95% or for the Hardy–Wein-
berg equilibrium (HWE) cut-off P ¼ 1.00E-07. Because of the
large number of low frequency SNPs included in the design of
the IBC array, and the desire to capture low MAF variants of
large effect across the large data set, no filtering was per-
formed based on MAF.
Statistical analyses
Evaluation of relatedness
To ensure the removal of cryptic relatedness and duplicate
samples from cohorts composed of unrelated individuals, pair-
wise identity-by-descent proportions were estimated between
all subjects within each participating study based on
identity-by-state (IBS) sharing and sample allele frequencies
using PLINK (49). For each set of duplicates or monozygotic
twins, and for those samples with an estimated pairwise IBS
threshold of .0.3, was retained the sample with the highest
genotyping call rate for analysis. In cohorts with extensive
family structure except the Amish study and PROCARDIS,
only founders were kept to the following steps of analysis
with a pairwise IBS check also implemented to ensure the
removal of related individuals. In the Amish study, family
structure was taken into account and the analysis was carried
out using the Mixed Model Analysis for Pedigree (MMAP)
software (J. O’Connell, 2008, Annual Meeting of The Ameri-
can Society of Human Genetics, Philadelphia, PA, USA,
abstract). When performing association computations in the
PROCARDIS study, family structures was also considered
as described elsewhere (20).
Evaluation of population stratification
Within each participating study, self-reported ethnicity was
verified by multidimensional scaling analysis of IBS distances
as implemented in PLINK, with HapMap CEU, YRI and
CHB/JPT samples included as reference standards. After per-
forming a prune of SNPs in LD (r2. 0.3), we used Eigenstrat
to compute 10 principal components (PCs) on the subset of
non-excluded individuals for use as covariates in the regres-
sion analyses (50,51). Self-reported ethnicity in the African,
Hispanic and East Asians individuals was also verified using
Eigenstrat.
BMI residuals
For each cohort, baseline BMI values were first regressed on
age, age-squared, and study site within ethnicity-sex stratum
and case–control status for CVD or T2D case–control
studies. Since test statistics for low frequency SNPs are
better calibrated if the phenotype is normally distributed, we
normal quantile transformed the residuals by obtaining the
rank order of the residual values within stratum, dividing the
rank value by (n + 1) and then taking the probit (inverse
normal) of this value. For sex-combined analysis, we com-
bined the male- and female-specific normal quantile trans-
formed residuals.
Association testing and meta-analysis (in Phase I through
V of the primary analyses)
The primary association analyses were performed using linear
regression with normal quantile transformed BMI residuals as
a continuous trait, as implemented in PLINK (49). We
assumed an additive genetic model and included covariate ad-
justment for the top 3 PCs of ancestry for individuals of EA
and 10 PCs for all other population subgroups. All analyses
were stratified by sex, ethnicity and CVD and/or T2D case–
control status if applicable. All meta-analyses were performed
using sample–size based as well as inverse-variance (standard
error)-based models in METAL (52), and between-study het-
erogeneity was assessed using the I2 metric (53). Additional
ethnicities were evaluated using the same approach as
described for individuals of EA. We then performed global
multi-ethnic meta-analysis on all available cohorts.
Different significance cut-off thresholds have been used in
previous studies utilizing the IBC array-based studies
(20,24). The standard Bonferroni approach for calculating a
significance threshold to declare a SNP associated is inappro-
priate considering the variants on the array were selected to
densely cover hypothesis-driven loci. In the CARe IBC
array studies, we utilized the ethnicity-specific local LD struc-
tures to estimate the effective numbers of independent tests.
We observed 26 500 and 20 500 independent observations
yielding statistical thresholds of P ¼ 1.89E-06 and P ¼
2.44E-06 in African-Americans and European Americans, re-
spectively, to maintain a false positive rate of 5% (54).
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Selection of look-up SNPs for additional replication studies
After Phase III meta-analysis of EA samples from individual-
and summary-level data sets, we generated a list of 29
SNPs (Supplementary Material, Table S5) for look up replica-
tions in six additional cohorts (Supplementary Material,
Table S10). We selected (i) two top BMI-associated SNPs in
Phase III, rs2229616 in MC4R (also an uncommon variant
with an MAF of 0.02 in EA individuals) and rs2075650 in
TOMM40-APOE-APOC1 (the novel finding up to Phase III);
(ii) four array-wide, yet not genome-wide significant SNPs
(those in FANCL-FLJ30838, TFAP2B, COL4A3BP-HMGCR
and SH2B1); (iii) 16 marginal signals in Phase III; and (iv)
seven SNPs that are of highest LD value (r2) with any
signal in each established BMI GWAS associated locus for
which IBC array has equal or better coverage. We then per-
formed association testing for the selected SNP set within
the six look-up studies.
Conditional analysis
We further examined all loci harboring evidence for associ-
ation for additional independent signals. Conditional analyses
was performed in PLINK (49) using a regression model that
included the lead SNP as a covariate, and surrounding SNPs
were evaluated for significance. Conditional analyses were
performed in 50 933 individuals of EA for which individual-
level data were available. We used a locus-wide Bonferroni-
corrected significance threshold, i.e. 0.05/(number of SNPs
tested within a given locus), when evaluating the conditional
analyses results. To directly assess the LD at each associated
locus, we used all the individual-level genotype data and
resolved haplotype structure using PHASE version 2.1.1
(55,56).
Sex-specific analysis
To test for sex-related differences in BMI-associated signals,
we performed sex-specific analysis after Phase III of our
primary analysis. We meta-analyzed individual and summary
level data for males only and females only, conducted a
second round meta-analysis including those two sets of
outputs, and checked heterogeneity measurement of each
SNP deemed with evidence for association in the Phase III
results. We used heterogeneity P-value ,0.05 between
males and females as SNP selection criteria.
Meta-analyses restricted to subsets of participating efforts
We then aggregated data sets with CVD cases only from the
case–control study designs, and we also grouped together
population- or community-based, and control-only studies
contributing individual- and summary-level data (specified in
Supplementary Material, Tables S8 and S9) and performed a
separate meta-analysis. Similarly, excluding participating
studies appearing in the recent GIANT BMI effort (16) (speci-
fied in Supplementary Material, Tables S8 and S9), a
meta-analysis on non-GIANT cohorts in the Phase I and II
stages was performed using the IBC array data sets.
Variance explained
The variance explained (adjusted R2) by associated SNPs was
calculated within EA cohorts with individual-level genotype
and phenotype data available (phase I) using a linear
regression model incorporating the age- and
age-squared-adjusted inverse normal transformed BMI resi-
duals as outcome, as well as 10 PCs as covariates. The
average variance explained, weighted by the sample size of
each contributing study, is reported.
Expression QTL analysis
eQTL analyses were conducted on array-wide significant loci
using monocyte and primary B-cells from 288 healthy blood
donors of European origin as recently described (57). Positive
selection was used to enrich CD19 + B cells and CD14+
monocytes from peripheral blood mononuclear cells prepared
from the whole blood of 288 healthy Europeans. Sample
purity was confirmed with flow cytometry and was found to
90–95% for the primary B-cells and 99% for monocytes.
We performed array based genome-wide gene expression pro-
filing using the HumanHT-12 v4 Expression BeadChips (Illu-
mina) and whole genome genotyping was performed using
Human OmniExpress-12v1.0 BeadChips (Illumina). Follow-
ing standard processing and quality control filtering, we per-
formed eQTL mapping at 651 210 SNPs for 283 samples
that passed QC criteria. Probes were tested against SNPs res-
iding within a 2.5 Mb window on either side of the probe as
designated by Illumina co-ordinates for association using a
Spearman rank model. All values presented represent uncor-
rected significance levels. Statistics were analyzed using R
and appropriate packages.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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